United States surgical and medical instruments and apparatus industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Surgical And Medical Instruments And Apparatus Stocks in USA: Prism Readiness Cohort 2

Name: Surgical And Medical Instruments And Apparatus Stocks in USA: Prism Readiness Cohort 2 comparison snapshot
Creator: Fliar BI Prism

A five-company surgical and medical instruments and apparatus cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 01 September 2026Not investment adviceRanked by Prism readiness

Readiness leaderFemasys · 52

Strongest available pathBecton Dickinson · -0.8%

Widest latest marginBecton Dickinson · 7.7%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1FEMY · Nasdaq

Femasys

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2011Suwanee, Georgia$27.3M market cap

View full Companies Radar profile

52Moderate

Snapshot price$3.26as of page date

Monthly-close return-97.6%five-year window

FY2025 revenue$0.00BFEMASYS INC

Net margin-812.3%FY2025

P/E snapshot-1.5xone ratio, not a verdict

Prism attention4.0%share across these five

Filing track recordRevenue, USD billions

+94.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 18.1%

52-week position6% through range

$2.02$22.20

News mentions388

Community mentions21partial coverage

U.S.-scope patents198

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal66/100
Management stability90/100
Market position7/100
Capital-event signal73/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2KIDS · Nasdaq

OrthoPediatrics

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2006Wilmington$600.5M market cap

View full Companies Radar profile

52Moderate

Snapshot price$23.00as of page date

Monthly-close return-64.9%five-year window

FY2025 revenue$0.24BORTHOPEDIATRICS CORP

Net margin-16.8%FY2025

P/E snapshot-32.4xone ratio, not a verdict

Prism attention9.7%share across these five

Filing track recordRevenue, USD billions

+141.1%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 24.6%

52-week position70% through range

$14.42$26.74

News mentions948

Community mentions12partial coverage

U.S.-scope patents212

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal73/100
Management stability90/100
Market position14/100
Capital-event signal63/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 6 M&A involvements, 2 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3PETV · OTC

PetVivo

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2021Minneapolis, Minnesota$22.8M market cap

View full Companies Radar profile

52Moderate

Snapshot price$0.60as of page date

Monthly-close return-77.8%five-year window

FY2025 revenue$0.00BPetVivo Holdings, Inc.

Net margin-741.6%FY2025

Prism attention2.7%share across these five

Filing track recordRevenue, USD billions

+8904.1%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 208.0%

52-week position1% through range

$0.59$1.69

News mentions263

Community mentions0partial coverage

U.S.-scope patents9

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal81/100
Management stability90/100
Market position7/100
Capital-event signal35/100
Innovation pulse20/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 1 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4TNDM · Nasdaq

Tandem Diabetes

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2008San Diego, California$1.48B market cap

View full Companies Radar profile

52Moderate

Snapshot price$21.28as of page date

Monthly-close return-82.2%five-year window

FY2025 revenue$1.01BTANDEM DIABETES CARE INC

Net margin-20.2%FY2025

P/E snapshot124.7xone ratio, not a verdict

Prism attention10.1%share across these five

Filing track recordRevenue, USD billions

+44.4%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 9.6%

52-week position54% through range

$11.46$29.65

News mentions991

Community mentions156partial coverage

U.S.-scope patents699

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal61/100
Management stability90/100
Market position7/100
Capital-event signal74/100
Innovation pulse15/100

Management signal

No leadership-churn flag in the model; 2 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5BDX · NYSE

Becton Dickinson

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1897Franklin Lakes$50.97B market cap

View full Companies Radar profile

50Moderate

Snapshot price$187.1as of page date

Monthly-close return-0.8%five-year window

FY2025 revenue$21.84BBECTON DICKINSON & CO

Net margin7.7%FY2025

P/E snapshot32.4xone ratio, not a verdict

Prism attention73.5%share across these five

Filing track recordRevenue, USD billions

+7.9%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1.9%

52-week position91% through range

$127.6$193.1

News mentions7.2K

Community mentions225partial coverage

U.S.-scope patents25013

Prism InsightsWhat sits behind the readiness signal
Observed risk 4/100higher means more observed risk

Earnings signal77/100
Management stability90/100
Market position33/100
Capital-event signal24/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 26 M&A involvements, 11 asset-acquisition events and 4 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 1 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Becton Dickinson

-0.8%

OrthoPediatrics

-64.9%

PetVivo

-77.8%

Tandem Diabetes

-82.2%

Femasys

-97.6%

Latest revenue

USD billions, official filing scope shown on each company card.

Becton Dickinson

$21.84B

Tandem Diabetes

$1.01B

OrthoPediatrics

$0.24B

Femasys

$0.00B

PetVivo

$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Becton Dickinson

7.7%

OrthoPediatrics

-16.8%

Tandem Diabetes

-20.2%

PetVivo

-741.6%

Femasys

-812.3%

Prism news attention

Normalized share across these five names; attention is not quality.

Becton Dickinson

73.5%

Tandem Diabetes

10.1%

OrthoPediatrics

9.7%

Femasys

4.0%

PetVivo

2.7%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized surgical and medical instruments and apparatus news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Becton Dickinson leads the conversation

It holds 73.5% of measured surgical and medical instruments and apparatus news attention and also carries the basket's largest revenue base at $21.84B.

Price path

Becton Dickinson leads the available price paths

Its monthly-close return is -0.8% for the five-year window. At the other end, Femasys is -97.6% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Becton Dickinson has the widest latest margin

Its FY2025 net margin is 7.7%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

OrthoPediatrics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -32.4x while its five-year window price return is -64.9%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · KIDS

OrthoPediatrics

948available Prism news records

Prism top themes

Earnings & financial performance

Price action & investor response

Capital allocation & transactions

Legal, arbitration & regulatory

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+19.7%146 latest 12m vs 122 prior 12m

Machine-classified coverage tone

77.5% positive-5.7 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

custom orthotics 18orthopedic specialty facility 16orthopedic hospital 16orthopedic surgery center 16earnings report 16orthopedic shoe insert 15orthopaedic center 14children's specialty hospital 11

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-25–2026-05-27 · trend and themes shown through 2026-05

Areas of research · TNDM

Tandem Diabetes

991available Prism news records

Prism top themes

Price action & investor response

Earnings & financial performance

Capital allocation & transactions

Leadership & governance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+9.0%157 latest 12m vs 144 prior 12m

Machine-classified coverage tone

83.3% positive-3.2 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

advanced diabetes devices 69insulin pump alarms 48insulin pump delivery 39automated insulin delivery 38insulin administration 30insulin-dependent diabetes control 29insulin vial storage 25type 1 diabetes insulin regimen 24

Keyword tag occurrences in available Prism news records.

Coverage: 2010-02-05–2026-06-12 · trend and themes shown through 2026-06

Areas of research · BDX

Becton Dickinson

7,210available Prism news records

Prism top themes

Price action & investor response

174

Capital allocation & transactions

131

Leadership & governance

Earnings & financial performance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-1.4%937 latest 12m vs 950 prior 12m

Machine-classified coverage tone

92.5% positive+3.9 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 37stock price 32investment deal 23stem cell banking 23stock surge 21cell-based therapies 18device-biologic combination 17antimicrobial resistance surveillance 16

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-13 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

TNDM

Tandem Diabetes

156 mentions

Products, pricing and logistics

Stock and valuation

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 156 records remained after filtering.

BDX

Becton Dickinson

225 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 225 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

FEMY

Femasys

through 2025-11-17

Earnings releases 12Leadership changes 2Regulatory 2Business contracts 1Company announcements 1

2025-11-17
Earnings releases
As per the news, the Q3 earnings report came out yesterday.
2025-11-10
Business contracts
today announced a significant initial order valued at approximately $500,000 USD for the commercial launch of FemBloc Permanent Birth Control in France and the Benelux region through its partnership with leading distributor Kebomed.
2025-05-30
Company announcements
Femasys Inc. (NASDAQ: FEMY) (the “Company” or “Femasys”), a leading biomedical innovator ... today announced the pricing of an underwritten public offering of 3,600,000 shares of its common stock at a public offering price of $0.85 per share and a separate concurrent private placement of 1,686,275 shares of its common stock at a price of $0.85 per share and a price of $1.02 per share to certain of its directors and officers.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

KIDS

OrthoPediatrics

through 2026-05-01

Earnings releases 34M&A 1

2026-05-01
Earnings releases
Taking a closer look at the P&L, our 2026 worldwide revenue of $59.4 million increased 13% compared to 2025.
2025-02-14
M&A
Orthopediatrics unveils deal to buy Apifix to gain MID-C system
2026-01-12
Earnings releases
Generated preliminary unaudited fourth quarter 2025 net revenue of $61.3 million, representing 16% growth compared to $52.7 million in the fourth quarter of 2024.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

PETV

PetVivo

through 2026-04-29

Earnings releases 11Leadership changes 7Company announcements 2Business contracts 1

2026-04-29
Business contracts
Peer to Peer Network's AI partner Tier 1 AI will install three tags and deliver up to 3,000 investor profiles a month.
2025-11-14
Earnings releases
Revenues totaled $303,000, up 51% from the same year-ago quarter.
2025-11-07
Company announcements
PetVivo Holdings, Inc. (OTCQX: PETV; OTCID: PETVW) and its wholly-owned subsidiary Petvivo Animal Health, Inc., a leading biomedical company delivering innovative medical devices and therapeutics for equines and companion animals, will hold a conference call on Friday, November 14, 2025 at 5:00 p.m. Eastern time to discuss results for the fiscal second quarter ended September 30, 2025.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TNDM

Tandem Diabetes

through 2026-02-20

Earnings releases 30Lawsuits 14Leadership changes 6Company announcements 1

2026-02-20
Earnings releases
Sales increased 3% year over year to $290.4 million, beating the consensus of $277.03 million.
2025-11-12
Leadership changes
Tandem Diabetes Care, Inc. announced the appointment of Sandra Beaver to its board of directors effective November 7, 2025.
2023-11-06
Lawsuits
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

BDX

Becton Dickinson

through 2026-03-20

Earnings releases 10M&A 10Asset acquisitions 4Company announcements 2Lawsuits 2

2026-03-20
Asset acquisitions
Waters completed its $18.8 billion buy of Becton Dickinson’s biosciences and diagnostics business last month.
2026-02-11
Earnings releases
Based on Becton Dickinson’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $5.25 billion and a net profit of $382 million.
2026-02-09
Business contracts
Waters on Wednesday announced the completion of its $18.8 billion deal to combine with Becton Dickinson's Biosciences & Diagnostic Solutions business.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Surgical And Medical Instruments And Apparatus Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary surgical and medical instruments and apparatus news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

surgical instruments market

9 sources77.7% extraction confidence

2019 extracted base$10.20B–$11.75B

2025 extracted forecast$11.50B–$21.52B

Implied source CAGR7.4%

increasing number of surgical proceduresrising prevalence of chronic diseasesincreasing prevalence of chronic diseases

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, Europe, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Surgical And Medical Instruments And Apparatus news pulse

84,236available Prism news records

Latest 12m volume+8.7%36648 vs 33721 records

Positive classified tone66.7%+5.2 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching instrument, medical, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates

7,802

medical drama series

7,076

cannabis legalization trends & economic impact

6,207

recreational marijuana usage

5,579

in-flight medical emergency protocols

4,688

medical marijuana laws & regulatory frameworks

3,617

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 7,316marijuana legalization arguments 6,389weed decriminalization debates 6,068cannabis industry regulations 5,880legal cannabis sales 5,791non-medical cannabis consumption 5,551medical cannabis regulations 5,272state cannabis economies 5,173

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of surgical procedures

9 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

cannabis legalization debates

7,802 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

6,624 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

uncertainty in reimbursements

7,008 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+8.7% news volume

The latest 12 months contain 36,648 matched records versus 33,721 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

66.7% positive · +5.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 3841 (Surgical And Medical Instruments And Apparatus), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 6–13. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Surgical And Medical Instruments And Apparatus Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 01 September 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Femasys leads the readiness ranking

Its Prism readiness score is 52/100, the highest in this five-company comparison.

Open Femasys in Companies Radar

Scale and margin leadership sit with Becton Dickinson and Becton Dickinson

Becton Dickinson has the largest displayed latest revenue at $21.84B; Becton Dickinson has the widest displayed latest margin at 7.7%.

Open Becton Dickinson in Companies Radar

Comparisons

Strongest versus weakest available price path

Becton Dickinson is -0.8% for its five-year window; Femasys is -97.6% for its five-year window.

Open Becton Dickinson in Companies Radar Open Femasys in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $21.84B for Becton Dickinson to $0.00B for PetVivo. Entity and filing-period labels remain visible on the company cards.

Open Becton Dickinson in Companies Radar Open PetVivo in Companies Radar

Anomalies

Becton Dickinson has the widest attention-readiness rank gap

It ranks #1 by measured news attention (73.5%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Becton Dickinson in Companies Radar

PetVivo shows a price-operating divergence to inspect

Its displayed filing-revenue change is +8904.1% while its available monthly-close return is -77.8%. The signs differ, but the two measures cover different windows and do not establish causality.

Open PetVivo in Companies Radar

Explanations

Attention measures coverage volume, not quality

Becton Dickinson's 73.5% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Becton Dickinson in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Femasys's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 52/100 score.

Open Femasys in Companies Radar

Stress-test the largest divergence before forming a view

Compare PetVivo's profile with Becton Dickinson's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open PetVivo in Companies Radar Open Becton Dickinson in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.